Nasdaq btai.

Nov 30, 2023 · The latest price target for BioXcel Therapeutics ( NASDAQ: BTAI) was reported by HC Wainwright & Co. on Wednesday, November 15, 2023. The analyst firm set a price target for 11.00 expecting BTAI ... When is BioXcel Therapeutics's earnings date? BioXcel Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 14th, 2024 based off last year's report dates. Learn more on BTAI's earnings history.A great week that adds to BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) one-year returns, institutional investors who own 48% must be happy (Simply Wall St.) Dec-22-22 07:00AM NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...

Nov 17, 2023 · On November 17, 2023, BTAI’s average trading volume was 3.13M shares. BTAI) stock’s latest price update. The stock of BioXcel Therapeutics Inc (NASDAQ: BTAI) has decreased by -0.47 when compared to last closing price of 4.25.Despite this, the company has seen a loss of -18.18% in its stock price over the last five trading days. The latest price target for . BioXcel Therapeutics (NASDAQ: BTAI) was reported by HC Wainwright & Co. on November 15, 2023.The analyst firm set a price target for $11.00 expecting BTAI to rise to ...BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.72 EPS, expectations were $-1.29. Operator: Good morning, and welcome to the BioXcel Therapeutics Conference Call, which will cover its alignment with the FDA on its ...

Fintel reports that on June 30, 2023, Mizuho reiterated coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy recommendation.. Analyst Price Forecast Suggests 205.94% Upside. As of June 2 ...

The latest price target for . BioXcel Therapeutics (NASDAQ: BTAI) was reported by HC Wainwright & Co. on Wednesday, November 15, 2023.The analyst firm set a price target for 11.00 expecting BTAI ...Find the latest on short interest for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.BTAI stock is down 57.2% as of Thursday morning. That comes as some 3.2 million shares change hands, as compared to its daily average trading volume of about 549,000 shares. Investors seeking out ...NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...

Nov 30, 2023 · The latest price target for BioXcel Therapeutics ( NASDAQ: BTAI) was reported by HC Wainwright & Co. on Wednesday, November 15, 2023. The analyst firm set a price target for 11.00 expecting BTAI ...

BioXcel Therapeutics ( BTAI 2.61%) stock is plummeting Monday. The clinical-stage biotech specialist's share price is down 44.6% as of 11:15 a.m. ET, according to data from S&P Global Market ...

Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...NEW HAVEN, Conn., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.72 EPS, expectations ...The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.To find the current corn price per bushel, there are a number of websites and places to look for predictions about the commodities market. Corn prices are listed on sites like NASDAQ and AgWeb if you want a quick answer.

The 5 analysts offering 12-month price forecasts for BioXcel Therapeutics Inc have a median target of 11.00, with a high estimate of 18.00 and a low estimate of 4.00. The median estimate ...BioXcel Therapeutics Stock (NASDAQ:BTAI), Short Interest Report. Short interest for BioXcel Therapeutics gives investors a sense of the degree to which investors are betting on the decline of ...A great week that adds to BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) one-year returns, institutional investors who own 48% must be happy (Simply Wall St.) Dec-22-22 07:00AM BioXcel Therapeutics (NASDAQ:BTAI) reported its Q3 earnings results on Tuesday, November 14, 2023 at 07:00 AM.. Here's what investors need to know about the announcement. Earnings. BioXcel ...Find the latest BioXcel Therapeutics, Inc. (BTAI) stock quote, history, news and other vital information to help you with your stock trading and investing.NEW HAVEN, Conn., April 29, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

Discover historical prices for BTAI stock on Yahoo Finance. View daily, weekly or monthly format back to when BioXcel Therapeutics, Inc. stock was issued. ... Nasdaq Futures 15,961.50-47.25 (-0.30 ...Bioxcel Therapeutics (BTAI) Stock Forecast & Price Target

27 Oct 2023 ... Fintel reports that on October 26, 2023, HC Wainwright & Co. reiterated coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy ...BXCL701 is an oral small molecule inhibitor of a class of enzymes called DPPs, specifically DPP8/9 and DPP4. Inhibition of DPP8/9 initiates the activation of the inflammasome and ultimately the activation of the innate immune system. BXCL701 is being developed by OnkosXcel Therapeutics, a wholly owned, clinical-stage subsidiary of …NEW HAVEN, Conn., July 22, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial ...BioXcel Therapeutics (NASDAQ:BTAI) announces that the FDA has accepted for filing the New Drug Application (NDA) for BXCL501, an investigational, orally dissolving thin film formulation of ...BioXcel Therapeutics (NASDAQ:BTAI), a biopharma company based in Connecticut, leverages AI and machine learning to develop innovative treatments for central nervous system and immuno-oncology ...Find the latest SEC Filings data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.

NEW HAVEN, Conn., Aug. 14, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

On track to submit complete NDA in Q1 2021. NEW HAVEN, Conn., Nov. 11, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage ...

Oct 5, 2023 · Fintel reports that on October 5, 2023, Truist Securities downgraded their outlook for BioXcel Therapeutics (NASDAQ:BTAI) from Buy to Hold . Analyst Price Forecast Suggests 650.57% Upside As of ... Back to BTAI Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.BioXcel Therapeutics, Inc. BTAI is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience.BioXcel Therapeutics, Inc. Common Stock (BTAI) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. Nasdaq | BTAI U.S.: Nasdaq BioXcel Therapeutics Inc. Watch NEW Set a price target alert Open Last Updated: Nov 17, 2023 at 10:39 a.m. EST Real time quoteNEW HAVEN, Conn., Dec. 27, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that the U.S. FDA has granted Fast Track Designation for ...Find the latest Institutional Holdings data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.BioXcel Therapeutics ( NASDAQ: BTAI ), based in Connecticut, develops treatments for CNS and cancer disorders, including FDA-approved Igalmi (marketed sublingual dexmedetomidine) and BXCL701 for ...14 Aug 2023 ... BioXcel Therapeutics (BTAI 2.37%) stock is plummeting Monday. The clinical ... NASDAQ: BTAI. BioXcel Therapeutics. Today's Change. (2.37%) $0.09.Shares of BioXcel Therapeutics ( BTAI -2.56%) were down 62% at 11 a.m. on Thursday after the company announced phase 3 trial results for Alzheimer's disease–related agitation therapy BXCL501 ...Shares of BioXcel Therapeutics ( BTAI -1.80%) were down 62% at 11 a.m. on Thursday after the company announced phase 3 trial results for Alzheimer's disease–related agitation therapy BXCL501 ...Nov 25, 2023 · Isaac Mitchell. November 25, 2023. Technologies. BioXcel Therapeutics Inc (NASDAQ:BTAI)’s traded shares stood at 0.4 million during the last session, with the company’s beta value hitting 0.78. At the close of trading, the stock’s price was $4.00, to imply an increase of 4.44% or $0.17 in intraday trading. The BTAI share’s 52-week high ...

The average one-year price target for BioXcel Therapeutics (NASDAQ:BTAI) has been revised to 14.28 / share. This is an increase of 5.88% from the prior estimate of 13.49 dated October 31, 2023. Based on analysts offering 12 month price targets for BTAI in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced its quarterly earnings results on Monday, August, 14th. The company reported ($1.83) earnings per share for the quarter, missing analysts' consensus estimates of ($1.72) by $0.11. The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.42 million.NEW HAVEN, Conn., Feb. 13, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...Instagram:https://instagram. tradovstestock price aurorabeigene ltdgolden ocean One share of BTAI stock can currently be purchased for approximately $3.89. Is BioXcel Therapeutics, Inc. listed on the NASDAQ or NYSE?Apr 5, 2023 · The FDA-approved Igalmi from BioXcel Therapeutics (NASDAQ:BTAI) for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults has garnered attention. ford f 150 lightning sales13f forms BTAI | Informative NASDAQ:BTAI Technical Analysis for NASDAQ:BTAI : If the price of BTAI breaks above the bullish line of $11.61, it may indicate a bullish signal, suggesting …BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ... hawaii dental insurance BRANFORD, Conn., June 07, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial ...Nov 29, 2023 · According to the issued ratings of 7 analysts in the last year, the consensus rating for BioXcel Therapeutics stock is Hold based on the current 5 hold ratings and 2 buy ratings for BTAI. The average twelve-month price prediction for BioXcel Therapeutics is $23.88 with a high price target of $40.00 and a low price target of $11.00. BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...